title: Chemotherapy for progressive pilocytic astrocytomas in the chiasmo-hypothalamic regions.
abstract: Over the past 25 years, we have treated 17 patients with chiasmo-hypothalamic astrocytomas. Before 1988, the initial treatments consisted of surgery and/or radiotherapy, while since 1989, 4 children (1 male, 3 females, aged 3-8 years) were treated primarily with chemotherapy. None of them was associated with neurofibromatosis. After a biopsy of the tumor, the intravenous administration of ranimustine (MCNU; 30-86 mg/m2) and/or nimustine (ACNU; 30.3-64.1 mg/m2) was given without radiation therapy. Chemotherapy was usually given as an out-patient, with a total of 5-13 courses. The total doses of MCNU and ACNU administered ranged from 150 to 570 mg and from 64.8 mg to 100 mg, respectively. After chemotherapy 2 patients showed clinical improvement and tumor regression on neuro-imaging, while one patient showed clinical improvement and tumor size stabilization on neuro-imaging. The remaining one child, however, showed a clinical worsening and tumor progression on neuro-imaging studies. He was thus treated with a second chemotherapy regimen with carboplatin and etoposide, which brought about tumor regression. The acute and subacute toxicity of chemotherapy was mild. All patients are now leading almost normal lives with a median of 43 months after diagnosis. Although a longer and more careful clinical observation is required, the authors conclude that chemotherapy with MCNU and/or ACNU may benefit patients with unresectable pilocytic astrocytoma requiring treatment. The advantages of this therapy include its mild side effects and the lack of any hospitalization in most patients. It may also delay the need for radiation therapy, which can have a deleterious effect on the young developing brain.
authors.affiliation: Department of Neurosurgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nishio
authors.forename: T
authors.initials: T
authors.lastname: Morioka
authors.forename: I
authors.initials: I
authors.lastname: Takeshita
authors.forename: T
authors.initials: T
authors.lastname: Shono
authors.forename: T
authors.initials: T
authors.lastname: Inamura
authors.forename: S
authors.initials: S
authors.lastname: Fujiwara
authors.forename: M
authors.initials: M
authors.lastname: Fukui
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007031:Hypothalamus / Q000473:pathology*; D007223:Infant; D008279:Magnetic Resonance Imaging; D008297:Male; D015376:Nimustine / Q000008:administration & dosage / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D009897:Optic Chiasm / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D015376:Nimustine; D005047:Etoposide; D016190:Carboplatin; C020766:ranimustine